Entyvio(vedolizumab)
Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Entyvio
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| crohn disease | EFO_0000384 | D003424 | K50 |
| enteritis | — | D004751 | K52.9 |
| ulcerative colitis | EFO_0000729 | D003093 | K51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3380 | Injection, vedolizumab, 1 mg |
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 3 | 10 | 16 | 16 | 39 | 84 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 8 | 11 | 16 | 31 | 69 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 1 | 1 | 4 | 23 | 30 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | — | 1 | 1 | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | 1 | — | 1 |
| Pouchitis | D019449 | EFO_0003921 | K91.850 | — | — | — | 1 | — | 1 |
| Self efficacy | D020377 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | — | 1 | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | — | 1 | — | — | 1 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | — | — | 1 | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 3 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 2 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 2 | 2 | — | — | — | 2 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | — | — | 1 | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | — | 1 |
| Celiac disease | D002446 | EFO_0001060 | K90.0 | — | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Diet therapy | D004035 | — | — | 1 | — | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 1 | 1 |
| Therapeutics | D013812 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vedolizumab |
| INN | vedolizumab |
| Description | Vedolizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743087 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09033 |
| UNII ID | 9RV78Q2002 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Entyvio – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,116 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
32,390 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use